Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Chao Liu is an Associate Professor at the Department of Biomedical Engineering , Southern University of Science and Technology (2024.11–present). Previously, he served as an Assistant Professor at the same institution (2019–2024.11) and completed a Postdoctoral Fellowship at New York University (2016–2019) with joint appointments in the Department of Biomedical Engineering and Orthopedics at NYU Langone Health . He holds a PhD in Biomedical Engineering (2016) and MASc in Mechanical Engineering (2010) from University of Toronto , following a BASc in Engineering Science (2008). Education : PhD (IBBME, U of Toronto, 2016), MASc (Mechanical Engineering, U of Toronto, 2010), BASc (Engineering Science, U of Toronto, 2008) His research focuses on mechanobiology of stem cells , bone tissue engineering , and functional implants . He investigates how mechanical forces modulate osteogenic and angiogenic stem cells, designs implants with micro-geometry to enhance cellular activity, and develops 3D real-time imaging modalities for bone repair processes. His work spans biomechanics , regenerative medicine , and cellular mechanotransduction . The selected publications from 2022 to 2010 reveal trends in mechanical force applications for bone regeneration, pharmacological impairments in healing, nanostructured biomaterials for stem cell differentiation, and microfluidic platforms for osteocyte studies. These works are published in journals like Bone , FASEB Journal , and ACS Applied Materials & Interfaces . Scientific Awards : International Conference BME Young Investigator Award (2019), IFMRS Travel Grant (2017), ASBMR Young Investigator Grant (2016), CIHR Travel Awards (2010–2014), Ontario Graduate Scholarship (2011–2013), Barbara and Frank Milligan Fellowship (2008, 2010) Chao Liu mentors graduate students, including Zhang Jianing (2022 Master’s graduate). His lab ( https://abtrl.bme.sustech.edu.cn/ ) recruits postdocs and research assistants for projects in mechanical force applications , micro-geometric implants , and 3D imaging . He has contributed to 14 journal articles with 714 citations and presented at 6 international conferences in the past three years.
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
Omer Bayraktar is a Group Leader at the Wellcome Sanger Institute , leading research in the Cellular Genomics Programme. His work focuses on decoding human brain cellular diversity using spatial transcriptomics , imaging , and functional screening to study neural complexity in health and disease. Bayraktar's educational background includes a PhD from HHMI under Chris Doe, investigating neural diversity development in Drosophila , followed by postdoctoral work at University of California, San Francisco and University of Cambridge as a Life Sciences Research Foundation Fellow. He developed a spatial transcriptomic pipeline during his postdoc to analyze astrocyte heterogeneity in the cerebral cortex. His research explores neural cell type mapping , glial-neuronal interactions , and cellular pathways in neurodevelopmental disorders . Recent publications emphasize 3D tissue mapping , multi-omic integration , and computational tools like Cell2fate and WebAtlas. His work bridges neurogenetics and computational biology to advance understanding of human tissue ecosystems. Bayraktar's lab collaborates with the Human Cell Atlas initiative and develops technologies such as automated histology pipelines and highly-multiplexed smFISH for molecular cell typing. His team also investigates glia-based therapies and astrocyte functional heterogeneity in neurodevelopmental contexts. Key scientific contributions include: Discovering astrocyte layer patterns independent of neuronal laminae Developing cell2location for spatial cell mapping Characterizing Drosophila neural stem cell models with human relevance Notable awards include the Life Sciences Research Foundation Fellowship during his postdoctoral training. His current group includes a PhD student , Senior Data Scientists , and Bioinformaticians .
Prof. Dr. Simon Schäfer leads the Schäfer Lab at the Technische Universität München , focusing on engineering advanced organoid systems to study human brain development, disease modeling, and repair mechanisms. His work bridges stem cell biology, gene editing, and bioengineering to develop personalized therapies for brain disorders. Stem Cell & Organoid Technology Neurodevelopmental Mechanisms Neurodegenerative Disease Models Gene Editing & Neuroimmune Interactions Translational Neuroscience Recent research emphasizes brain organoid development, microglia phenotypes, and neurodevelopmental timing anomalies in autism. His team’s work also explores zika virus interactions with glioblastoma stem cells and neuronal plasticity in psychiatric disorders. Scientific awards and funding include support from the Deutsche Forschungsgemeinschaft (DFG), Brain & Behavior Research Foundation (BBRF), and Munich Cluster for Systems Neurology (SyNergy). Collaborations span institutions like the TUM Center for Organoid Systems. Advises 6 students (2 PhD, 1 MSc, 3 associated) Labs include Schäfer Lab, COS@TranslaTUM Contact: simon.schafer@tum.de
Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models
Dana Pe'er is a Professor and Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) of Memorial Sloan Kettering Cancer Center. She is also an Investigator of the Howard Hughes Medical Institute and holds the Alan and Sandra Gerry Endowed Chair. Dr. Pe'er leads an interdisciplinary research group that combines advanced genomics approaches with machine learning to address fundamental questions in biomedical science, with particular focus on cancer biology, developmental biology, and immunology. Dr. Pe'er earned her PhD from Hebrew University in Jerusalem, Israel. Her academic journey includes a postdoctoral fellowship with George Church at Harvard Medical School. Before joining Memorial Sloan Kettering Cancer Center in 2016, she held faculty positions at Columbia University. Dr. Pe'er's research focuses on understanding cellular plasticity, the consequences of intra-tumor heterogeneity, cancer evolution and metastasis, and the mechanisms by which regulatory circuits go awry in disease. Her lab combines single-cell and spatial profiling technologies with machine learning approaches to investigate gene regulation, cellular plasticity, and cell-cell communication in the contexts of cancer, immunity, and development. They are particularly interested in how organisms develop from a single cell to generate diverse cell types, how epigenetic control rewires during development, and how cells communicate to execute multicellular responses. Analysis of Dr. Pe'er's recent publications reveals a strong focus on developing computational methods for single-cell and spatial genomics data analysis. Her work spans cancer types including pancreatic, prostate, colorectal, and breast cancer, with emphasis on tumor heterogeneity, metastasis mechanisms, and cellular plasticity. A significant portion of her research involves creating novel algorithms and tools like CellRank, REUNION, and SEACells that enable researchers to extract meaningful biological insights from complex genomic datasets. 2023 Class of 2023 Inductee - American Academy of Cancer Research (AACR) Academy 2023 Innovator Award - International Society for Computational Biology (ISCB) 2021 Fellow - International Society for Computational Biology (ISCB) Howard Hughes Medical Institute Investigator (2021) 2019 Ernst W. Bertner Memorial Award - University of Texas MD Anderson Cancer Center 2016 Lenfest Distinguished Faculty Award - Columbia University 2014 Director's Pioneer Award - National Institutes of Health 2014 Overton Prize - International Society for Computational Biology (ISCB) Dr. Pe'er is known for her dedicated mentorship approach, describing herself as "a mama bear" who cares deeply about her trainees while expecting independence, innovation, and hard work. She mentors numerous PhD students and postdocs in her lab. Her HHMI Investigator award provides approximately $9 million over seven years, enabling ambitious research directions. She also collaborates extensively with the Single-cell Analytics and Innovation Lab (SAIL) at MSK to generate new data from emerging technologies, working closely with wet-lab collaborators at MSK and beyond to apply computational methods to cutting-edge datasets across multiple disease areas. The Pe'er Lab is an interdisciplinary group of computational biologists with diverse backgrounds ranging from pure mathematics to clinical medicine. They work closely with wet-lab collaborators to apply their computational methods to cutting-edge datasets across cancer, immunology, and developmental biology. The lab is described as open, supportive, collaborative, and fun, with access to world-class facilities at the Sloan Kettering Institute. Dr. Pe'er's work continues to push the boundaries of computational biology and cancer research, with the ultimate goal of developing more effective, personalized therapies for cancer patients.
Todd A. Alonzo is a Professor of Research in the Department of Preventive Medicine at the University of Southern California . As Group Statistician for the Children's Oncology Group , he focuses on statistical methods for biomarker analysis, medical diagnostic testing, and clinical trial design in pediatric acute myeloid leukemia (AML). Education: B.S. in Statistics, California State Polytechnic University (1994) MS and PhD in Biostatistics, University of Washington (1997, 2000) Research Interests include: Development of statistical frameworks for diagnostic accuracy Genomic and proteomic profiling in AML Pharmacogenomic score systems for chemotherapy response Non-inferiority trial design in low-event-rate settings Health disparities in pediatric oncology Scientific Awards : Fellow, American Statistical Association (2018) Outstanding Teacher Award, International Society for Magnetic Resonance in Medicine (2017) NIH Predoctoral Cardiovascular Biostatistics Training Grant (1995) ENAR Biometrics Society Distinguished Student Paper Award (1999) WNAR Biometrics Society Best Student Oral Presentation (1999) Leadership & Service includes editorial board memberships (Biometrics, Pediatric Blood & Cancer, Biometrical Journal), reviewer for 30+ scientific journals, and roles on multiple Data Safety and Monitoring Boards. He served as President of the International Biometric Society Western Northern America Region (WNAR) in 2009.
Lin He is the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research and Professor of Cell Biology and Physiology at the University of California, Berkeley. His laboratory focuses on understanding the biological functions of non-coding RNAs in development and disease, with particular emphasis on microRNAs (miRNAs) in cancer, stem cell biology, and developmental processes. He developed the CRISPR-EZ method for highly efficient mouse genome editing, significantly advancing genetic research. Research interests include miRNAs' roles in tumor progression, metastasis, and pluripotency regulation in stem cells. His work bridges mouse genetics, genomics, and molecular biology to uncover mechanisms governing non-coding RNA functions. Current projects address miRNAs in oncogenesis, stem cell fate determination, and the interplay between non-coding RNAs and retrotransposons in development. Key contributions include identifying miRNA networks in cancer pathways, demonstrating miRNA requirements for ciliogenesis and lung development, and advancing CRISPR-based genome editing techniques. His interdisciplinary approach integrates genetic, genomic, and cellular tools to explore fundamental questions in biology and medicine. Lab website: helabucb.org CRISPR-EZ technology enables 100% genome editing efficiency in mouse zygotes Pioneering studies on miRNA regulation of PTEN, p53, and oncogene pathways
Peter A. Jones is President and Chief Scientific Officer at the Van Andel Institute (VAI) in Grand Rapids, Michigan, where he leads the Department of Epigenetics. He previously served as Director of the USC Norris Comprehensive Cancer Center from 1993 to 2011 and has been a central figure in advancing epigenetics research, particularly in cancer. His laboratory investigates DNA methylation, chromatin dynamics, and epigenetic therapies. Research Interests: Dr. Jones's work centers on epigenetic mechanisms in cancer, including DNA methylation, histone modifications, nucleosome positioning, and the therapeutic potential of epigenetic drugs. His research has pioneered the use of DNA methylation inhibitors like 5-azacytidine and explored viral mimicry as a mechanism for immune activation in cancer. He also studies transposable elements and their role in gene regulation and immune response. Publication Trends: His recent publications (2021–2024) reveal a strong focus on the interplay between epigenetics and immunotherapy, particularly how DNA methyltransferase inhibitors (DNMTi) induce viral mimicry, enhance immune recognition, and improve responses to checkpoint blockade. Studies span hematological malignancies, solid tumors, and T cell biology, with frequent collaboration with Stephen Baylin and others. Scientific Awards: Member, National Academy of Sciences Member, National Academy of Medicine Fellow, AACR Academy Fellow, AAAS Fellow, American Academy of Arts and Sciences Kirk A. Landon Award for Basic Cancer Research (2009) Medal of Honor, American Cancer Society (2011) Outstanding Investigator Grant, NCI Harvey Prize (2024) Advising and Grants: Dr. Jones mentors multiple postdoctoral fellows, graduate students, and research scientists. His lab is supported by major grants, including the VAI-SU2C Epigenetics Dream Team, which has launched 15 clinical trials. He has received sustained funding from the National Cancer Institute and collaborates with institutions worldwide to advance epigenetic therapies. Labs and Teams: He leads the Peter Jones Laboratory at VAI, a multidisciplinary team investigating epigenetic regulation in cancer. The lab includes computational biologists, clinical researchers, and molecular biologists, working on both basic mechanisms and translational applications. The team is part of larger collaborative initiatives such as the VAI-SU2C Epigenetics Dream Team and the International Linked Clinical Trials Program.
Hsueh-Chia Chang is the Bayer Professor of Chemical Engineering in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame's College of Engineering. He also holds a concurrent faculty position in the Department of Aerospace and Mechanical Engineering. As Principal Investigator of the Chang Lab, he leads cutting-edge research in microfluidic and nanofluidic technologies for biomedical applications. Prof. Chang received his B.S. in Chemical Engineering from Caltech in 1976, followed by M.S. and Ph.D. degrees in Chemical Engineering from Princeton University in 1977 and 1980, respectively. His academic journey has established him as a leader in the field of microfluidics and biosensing technologies. Chang's research focuses on developing low-cost liquid biopsy nanotechnologies for cancer screening and therapy management. His lab specializes in microfluidic and nanofluidic research coupled with electrokinetics, optics, plasmonics and acoustics for biosensing applications. Key research areas include Electrokinetics & Biosensing, Optics & Plasmonics, Nanoelectrokinetics, and Droplet Microfluidics. The Chang Lab has developed innovative platforms that can isolate and sort tumor cells, exosomes, microvesicles, lipoproteins, and stress granules from blood samples, then lyse these structures to release RNA/protein biomarkers for detection and quantification. His recent publications reveal a strong focus on extracellular vesicle diagnostics, cancer biomarker detection, and point-of-care diagnostic technologies. The research spans multiple disciplines including oncology, cardiology, and neurology, with applications for pancreatic, liver, breast, ovarian, and lung cancers as well as myocardial infarction diagnosis. Fellow of American Institute of Medical and Biological Engineering (2025) Provost Research Achievement Award, Notre Dame (2024) Fellow of the National Academy of Inventors (2020) Lifetime Achievement Award, American Electrophoresis Society (2019) Fellow of the American Physical Society (1997) Presidential Young Investigator Award, NSF (1985) Prof. Chang has advised over 50 PhD students and postdocs who have gone on to prominent positions in academia and industry. His lab has secured significant funding and has commercialized several technologies through startups like Aopia Biosciences, which launched NanoEx at ISEV 2024. The Chang Lab maintains active collaborations with medical researchers for validating their diagnostic platforms against various cancers and cardiac conditions.
Suradip Das is a Research Assistant Professor in the Department of Neurosurgery at the Perelman School of Medicine, University of Pennsylvania, where he serves as a Senior Research Investigator. His work bridges neural engineering and regenerative medicine to address critical challenges in nerve and muscle repair. His academic training includes: B.Tech in Biotechnology from Heritage Institute of Technology (2010) PhD in Biosciences and Bioengineering from Indian Institute of Technology Guwahati (2016) Dr. Das specializes in biomaterials development , peripheral nerve injury models , neuromuscular interface engineering , and stem cell-based regeneration . His research pioneers innervated tissue-engineered muscle constructs, demonstrating how motor neurons and endothelial cells synergistically enhance skeletal myocyte maturation. He innovates custom mechanobioreactors that apply tensile forces to guide nanofiber alignment for optimal myofiber formation, significantly advancing volumetric muscle loss treatments. Analysis of his 15 most recent publications reveals a dominant focus on neuromuscular regeneration (75% of articles), with emerging exploration of psychedelic compounds in neural repair. His work consistently integrates human iPSC-derived models , multi-cellular co-cultures , and large-animal validation to address translational gaps. Key trends include optogenetic control of motor units (2023), porcine nerve injury models (2020), and the critical role of pre-innervation in creating pro-regenerative microenvironments (2020-2022). As a core member of the Cullen Lab, Dr. Das collaborates on developing biofabricated neural microtissues for delayed nerve fusion and rapid functional recovery. His research directly informs clinical strategies for peripheral nerve repair and muscle regeneration through rigorous mechanistic studies and innovative engineering solutions.
Foteini Mourkioti is an Associate Professor at the University of Pennsylvania's Perelman School of Medicine , with a joint appointment in the Graduate Groups of Cell and Molecular Biology and Bioengineering . She co-directs the Musculoskeletal Regeneration Program at the Penn Institute of Regenerative Medicine and leads the McKay Orthopaedic Research Laboratory . Research Interests : Muscle Stem Cell Biology Mechanobiology Muscle Regeneration Telomere Biology in Muscular Diseases Fibrodysplasia Ossificans Progressiva (FOP) Cardiomyopathy and Aging Key Research Contributions : Developed the Pax7EGFP mouse model for real-time muscle stem cell tracking Discovered telomere shortening as a critical factor in Duchenne Muscular Dystrophy Elucidated the role of NF-κB in muscle stem cell dysfunction Identified Piezo1's role in stem cell morphological states Characterized fibro-adipogenic progenitor dynamics in FOP Scientific Awards : NIH/NHLBI R01 grant recipient (2019) NASA grant awardee (2020, 2017) American Heart Association grant (2017) Muscular Dystrophy Association grant (2019) University Research Foundation grant (2018) Publications & Collaborations : Over 25 publications in high-impact journals like Science Advances , Nature Protocols , and Cell Reports . Collaborates with Penn Cardiovascular Institute and Pennsylvania Muscle Institute.
Evelyn Lake is an Associate Professor in the Department of Radiology and Biomedical Imaging at Yale University, with affiliations to the Wu Tsai Institute and Yale Biomedical Imaging Institute. Her research focuses on functional neuroimaging, particularly using rodent models to study brain connectivity, neurovascular coupling, and disorders like Alzheimer’s disease and autism spectrum disorder. PhD in Medical Biophysics, University of Toronto (2016) Postdoctoral Associate, Yale University (2019) BSc (Honors) in Biophysics, University of Guelph (2010) Her work spans multimodal imaging techniques (e.g., simultaneous Ca2+ and fMRI), examining how genetic mutations (e.g., PTEN, KATNAL2) affect cerebrospinal fluid dynamics and neuronal connectivity. She investigates longitudinal changes in Alzheimer’s models and methodological aspects of animal neuroimaging, such as sample size optimization and awake imaging protocols. Recent publications highlight her contributions to understanding autism-related white matter abnormalities, transdiagnostic connectome predictive modeling, and the impact of neurovascular uncoupling in awake mice. Collaborations include Todd Constable, Francesca Mandino, Xilin Shen, and Xenophon Papademetris.
